Hepatic arterial infusion of gemcitabine and oxaliplatin for treating non-resectable intra-hepatic cholangiocarcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the efficacy of intra-arterial administration of gemcitabine and oxaliplatin as a second-line treatment for patients with non-metastatic unresectable intra-hepatic cholangiocarcinoma. The approach aims to enhance drug delivery directly to the tumor site, leveraging the unique vascularization of hepatic tumors. The study will evaluate the objective response rate at four months post-treatment, with a focus on minimizing systemic toxicity while maximizing local drug concentration. Previous studies have indicated promising results with this method, suggesting a potential for improved patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically-proven intrahepatic cholangiocarcinoma previously treated by first-line systemic therapy
* Absence of extra-hepatic metastasis or peritoneal carcinomatosis (as demonstrated by CT-scan)
* General health status : World Health Organization Performance Status = 0, 1
* Estimated life expectancy \> 3 months
* Disease that is not suitable for resection with a curative intent, as validated by a multidisciplinary committee with at least one senior hepatic surgeon
* At least one measurable lesion according to RECIST 1.1 criteria
* Platelets ≥100,000/mm3, polynuclear neutrophils ≥ 2000/mm3 , hemoglobin 9g/dL (even transfused patients can be included)
* Creatininemia \< 1.5 mol/L
* Creatinine clearance \> 30 mL/min
* Bilirubinemia ≤2 N (after biliary drainage if necessary)
* Aspartate and Alanine Transaminase ≤ 5 mol/L
* Reference hepatic MRI (according to the foreseen protocol) done during the 30 days preceding the 1st cycle of treatment
* Written informed consent
* National health insurance cover

Exclusion Criteria:

* Patients with cholangiocarcinoma of the gallbladder or common bile duct or those with hepatocholangiocarcinoma or a Klatskin tumor
* Patients who are eligible for surgical resection or liver transplantation
* Extra-hepatic metastases (Pulmonary micronodules \<7mm without uptake on positron emission tomography are not a contra-indication)
* Presence of clinical ascites
* History of intra-arterial therapy or more than one line of systemic treatment
* Contra-indication or grade 3-4 allergy to any of the treatment drugs Gemcitabine, Oxaliplatin (notably myelosuppression developped before the beginning of the first cycle of therapy, peripheral sensory neuropathy before the first cycle of therapy, severe renal failure)
* Grade 2 peripheral neuropathy
* Ongoing participation or participation within the 21 days prior to inclusion in the study in another therapeutic trial with an experimental drug
* Concomitant systemic treatment with immunotherapy, chemotherapy or hormone therapy
* Serious non-stabilized disease, active uncontrolled infection or other serious underlying disorder likely to prevent the patient from receiving the treatment
* Pregnancy (beta-human chorionic gonadotropin positive), breast-feeding or the absence of effective contraception for women of child-bearing age
* Another cancer in the 5 years preceding or at the time of inclusion in the trial (except for in situ cervical cancer or basal cell carcinoma of the skin)
* Allergy or contra-indication to iodine contrast agents (thyrotoxicosis, allergy to the active substance or excipients)
* Treatment with anticoagulants (heparin or AVK) that cannot be interrupted for 12 hours
* Treatment with anti-platelets that cannot be interrupted for 5 days for aspirin or Plavix.
* Contra-indication for use of an intra-arterial approach (severe arteriopathy)
* Legal incapacity (persons in custody or under guardianship)
* Deprived of liberty Subject (by judicial or administrative decision)
* Impossibility to sign the informed consent document or to adhere to the medical follow-up of the trial for geographical, social or psychological reasons
* Contraindication for the MRI : Pacemaker or neurosensorial stimulator or implantable defibrillator, cochlear implant, ferromagnetic foreign body similar to the nervous structure.

Where it's running

• Amiens University Hospital
  Amiens, France Recruiting
• Angers University Hospital
  Angers, France Recruiting
• Bordeaux University Hospital
  Bordeaux, France Recruiting
• Centre Georges François Leclerc
  Dijon, France Recruiting
• Uhmontpellier
  Montpellier, France Recruiting
• Hôpital Européen Georges Pompidou
  Paris, France Recruiting

Study contacts

• Principal investigator: Boris GUIU — University Hospital, Montpellier
• Study coordinator: Chloé Guillot
• Email: chloe-guillot@chu-montpellier.fr
• Phone: +33467337327

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Preoperative Right Hepatic Artery Embolization to enable surgery for advanced perihilar cholangiocarcinoma

  A single-arm study tests whether embolizing the right hepatic artery before surgery helps patients with unresectable, locally advanced perihilar cholangiocarcinoma become eligible for radical liver surgery.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07326189

• Personalized treatment approach for rectal adenocarcinoma

  This study is testing a personalized treatment plan for people with rectal adenocarcinoma to see if a mix of less invasive surgeries and special therapies can improve their quality of life and reduce the chance of cancer coming back.

  Recruiting Fondazione del Piemonte per l'Oncologia · Candiolo, Turin · NCT06952101

• Investigating liver and pancreas surgery followed by transplantation for advanced cholangiocarcinoma

  This study is testing a new surgery method for patients with advanced bile duct cancer to see if removing the liver and pancreas together, followed by a liver transplant, can help them live longer.

  Recruiting Oslo University Hospital · Oslo · NCT06850753

• Combination therapy for patients with unresectable intrahepatic cholangiocarcinoma

  This study is testing a new combination of chemotherapy and targeted therapy to see if it can shrink tumors in patients with a type of liver cancer that can't be surgically removed.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT06192797

• Combination treatment for advanced bile duct cancer

  This study is testing a new combination treatment for patients with advanced bile duct cancer that can't be surgically removed to see if it helps them feel better and live longer.

  Recruiting Phase 2 Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT05655949

• 64Cu-DOTA-Pembrolizumab PET to See If Treatment Is Working in Stage IV NSCLC

  This study tests a new PET imaging agent paired with pembrolizumab to see if it can show which tumors are still responding in adults with stage IV NSCLC who are already receiving pembrolizumab.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07619599

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.